Aytu BioPharma, Inc. announced the appointment of Abhinav "Abi" Jain of Nantahala Capital Management, LLC as the Company's Board of Directors as Board of Directors. In connection with Mr. Jain's appointment to the
Board, upon the closing of the Offering, Mr. Jain will be appointed to the Company's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Abi Jain is an Analyst at Nantahala, focused on investments in various sectors, including specialty and generic pharmaceuticals. Prior to joining Nantahala in 2019, Mr. Jain was an Associate at Angelo, Gordon &Co., an alternative asset manager based in New York from 2015-2017. At Angelo, Gordon &Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with an M.B.A. with honors in Finance and Entrepreneurial Management.